<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>ONCASPAR- pegaspargaseÂ injection, solutionÂ </strong><br></p></div>
<div id="Highlights" class="Highlights"><table cellspacing="5" cellpadding="5" width="100%" style="table-layout:fixed"><tr><td align="left" valign="top"><div>
<h1>HIGHLIGHTS OF PRESCRIBING INFORMATION</h1>
<div class="HighlightsDisclaimer"></div>
<div class="HighlightSection">
<h1 class="Highlights"><span>RECENT MAJOR CHANGES</span></h1>
<div>
<p class="Highlighta">Indications and Usage,Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â 9/2006<br>Â Â Â Â Â Â Â Â Â First line <span class="product-label-link" type="condition" conceptid="134305" conceptname="Acute lymphoid leukemia">acute lymphoblastic leukemia</span> (ALL) <a href="#E81603C2-F0E3-4180-841E-3D78B5CD8BE0">(1.1)</a> </p>
<br><p class="Highlighta">Contraindications,Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â 9/2006<br>Â Â Â Â Â Â Â Â Â History of serious <span class="product-label-link" type="condition" conceptid="4130722" conceptname="Thrombosis">thrombosis</span> with prior L-asparaginase therapy <a href="#B96ED3ED-EE6D-43E3-A106-C0FA789F66B8">(4)</a> </p>
</div>
</div>
<div></div>
<div class="HighlightSection">
<h1 class="Highlights"><span>INDICATIONS AND USAGE</span></h1>
<div>
<p class="Highlighta">Oncaspar<span class="Sup">Â®</span> is indicated as a component of a multi-agent chemotherapeutic regimen for treatment of patients with: </p>
<ul>
<li>First line <span class="product-label-link" type="condition" conceptid="134305" conceptname="Acute lymphoid leukemia">acute lymphoblastic leukemia</span> <a href="#E81603C2-F0E3-4180-841E-3D78B5CD8BE0">(1.1)</a>
</li>
<li><span class="product-label-link" type="condition" conceptid="134305" conceptname="Acute lymphoid leukemia">Acute lymphoblastic leukemia</span> and <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> to asparaginase <a href="#DA8969B8-7548-45EC-9930-9207FBF2CA4B">(1.2)</a>
</li>
</ul>
</div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DOSAGE AND ADMINISTRATION</span></h1>
<div><ul>
<li>2,500 IU/m<span class="Sup">2</span> intramuscularly (IM) or intravenously (IV) no more frequently than every 14 days. <a href="#AF77E56D-DD70-42C4-987D-AB20DCF8CE81">(2.1)</a>
</li>
<li>For IM administration, limit the volume at a single injection site to 2 mL; if greater than 2 mL, use multiple injection sites. <a href="#A3868AA5-D1ED-4CD6-9B0D-87D84C3CAFC7">(2.2)</a>
</li>
<li>For IV administration, give over a period of 1 to 2 hours in 100 mL of sodium chloride or dextrose injection 5%, through an infusion that is already running. <a href="#A3868AA5-D1ED-4CD6-9B0D-87D84C3CAFC7">(2.2)</a>
</li>
<li>Do not administer Oncaspar<span class="Sup">Â®</span> if drug has been frozen, stored at room temperature for more than 48 hours, or shaken or vigorously <span class="product-label-link" type="condition" conceptid="436087" conceptname="Excitement">agitated</span>. <a href="#A4A10BC7-5D33-4BB8-A9D1-0296CD5EA194">(2.3)</a>
</li>
</ul></div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DOSAGE FORMS AND STRENGTHS</span></h1>
<div><ul><li>3,750 IU/5 mL single-use vial. <a href="#FF701AF5-87FF-46FA-838D-CC2B5548A698">(3)</a>
</li></ul></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>CONTRAINDICATIONS</span></h1>
<div><ul>
<li>History of serious <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergic reactions</span> to Oncaspar<span class="Sup">Â®</span><a href="#B96ED3ED-EE6D-43E3-A106-C0FA789F66B8">(4)</a>
</li>
<li>History of serious <span class="product-label-link" type="condition" conceptid="4130722" conceptname="Thrombosis">thrombosis</span> with prior L-asparaginase therapy <a href="#B96ED3ED-EE6D-43E3-A106-C0FA789F66B8">(4)</a>
</li>
<li>History of <span class="product-label-link" type="condition" conceptid="4192640" conceptname="Pancreatitis">pancreatitis</span> with prior Lâ€‘asparaginase therapy <a href="#B96ED3ED-EE6D-43E3-A106-C0FA789F66B8">(4)</a>
</li>
<li>History of serious hemorrhagic events with prior L-asparaginase therapy <a href="#B96ED3ED-EE6D-43E3-A106-C0FA789F66B8">(4)</a>
</li>
</ul></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>WARNINGS AND PRECAUTIONS</span></h1>
<div><ul>
<li>If the following occur - discontinue Oncaspar<span class="Sup">Â®</span>:<br>Â Â Â Â <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">Anaphylaxis</span> or serious <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergic reactions</span> <a href="#F43A95EB-8471-40AC-BA00-AD3D0871E80F">(5.1)</a><br>Â Â Â Â <span class="product-label-link" type="condition" conceptid="4130722" conceptname="Thrombosis">Thrombosis</span> <a href="#A8BEB43E-9C54-4106-8CFD-5FEDC8C3DE17">(5.2)</a><br>Â Â Â Â <span class="product-label-link" type="condition" conceptid="4192640" conceptname="Pancreatitis">Pancreatitis</span> <a href="#C97ED96C-F64A-4678-BD35-52072A86324A">(5.3)</a>
</li>
<li><span class="product-label-link" type="condition" conceptid="44808385" conceptname="Pre-diabetes">Glucose intolerance</span>, in some cases irreversible, can occur <a href="#A016C76D-E3AE-421E-AC91-12A10B009249">(5.4)</a>
</li>
<li><span class="product-label-link" type="condition" conceptid="432585" conceptname="Blood coagulation disorder">Coagulopathy</span> can occur.  Perform appropriate monitoring. <a href="#A5A0BA9F-A525-44ED-954D-600B56006FD2">(5.5)</a>
</li>
</ul></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>ADVERSE REACTIONS</span></h1>
<div><p class="Highlighta">Most common adverse reactions (â‰¥ 2%) are <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergic reactions</span> (including <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylaxis</span>), central nervous system (CNS) <span class="product-label-link" type="condition" conceptid="4130722" conceptname="Thrombosis">thrombosis</span>, <span class="product-label-link" type="condition" conceptid="432585" conceptname="Blood coagulation disorder">coagulopathy</span>, elevated transaminases, <span class="product-label-link" type="condition" conceptid="4032334" conceptname="Hyperbilirubinemia">hyperbilirubinemia</span>, <span class="product-label-link" type="condition" conceptid="4214376" conceptname="Hyperglycemia">hyperglycemia</span>, and <span class="product-label-link" type="condition" conceptid="4192640" conceptname="Pancreatitis">pancreatitis</span>. <a href="#A038322E-2929-4DED-8320-B5A888855461">(6)</a> </p></div>
<div>
<div></div>
<div></div>
</div>
<div>
<div></div>
<div></div>
</div>
<div></div>
</div>
<div></div>
<div>
<div></div>
<div></div>
<div></div>
</div>
<div></div>
<div></div>
<div>
<div></div>
<div></div>
<div></div>
</div>
<div><div></div></div>
<div>
<div></div>
<div></div>
</div>
<div><div></div></div>
<div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<p class="HighlightsSeeReference">See 17 for PATIENT COUNSELING INFORMATION.</p>
<p class="HighlightsRevision">Revised: 7/2006</p>
</div></td></tr></table></div>
<div id="Index" class="Index"><table cellspacing="5" cellpadding="5" width="100%" style="table-layout:fixed"><tr><td align="left" valign="top"><div>
<h1 class="Colspan">FULL PRESCRIBING INFORMATION: CONTENTS<a href="#footnote-content" name="footnote-reference-content">*</a>
</h1>
<h1><a href="#section-2" class="toc">1  INDICATIONS AND USAGE</a></h1>
<h2><a href="#section-2.1" class="toc">1.1 First Line <span class="product-label-link" type="condition" conceptid="134305" conceptname="Acute lymphoid leukemia">Acute Lymphoblastic Leukemia</span> (ALL)</a></h2>
<h2><a href="#section-2.2" class="toc">1.2 <span class="product-label-link" type="condition" conceptid="134305" conceptname="Acute lymphoid leukemia">Acute Lymphoblastic Leukemia</span> and <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity</span> to Asparaginase</a></h2>
<h1><a href="#section-3" class="toc">2  DOSAGE AND ADMINISTRATION</a></h1>
<h2><a href="#section-3.1" class="toc">2.1 Recommended Dose</a></h2>
<h2><a href="#section-3.2" class="toc">2.2 Instructions for Administration</a></h2>
<h2><a href="#section-3.3" class="toc">2.3 Preparation and Handling Precautions</a></h2>
<h1><a href="#section-4" class="toc">3  DOSAGE FORMS AND STRENGTHS</a></h1>
<h1><a href="#section-5" class="toc">4  CONTRAINDICATIONS</a></h1>
<h1><a href="#section-6" class="toc">5  WARNINGS AND PRECAUTIONS</a></h1>
<h2><a href="#section-6.1" class="toc">5.1 <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">Anaphylaxis</span> and Serious <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Allergic Reactions</span></a></h2>
<h2><a href="#section-6.2" class="toc">5.2 <span class="product-label-link" type="condition" conceptid="4130722" conceptname="Thrombosis">Thrombosis</span></a></h2>
<h2><a href="#section-6.3" class="toc">5.3 <span class="product-label-link" type="condition" conceptid="4192640" conceptname="Pancreatitis">Pancreatitis</span></a></h2>
<h2><a href="#section-6.4" class="toc">5.4 <span class="product-label-link" type="condition" conceptid="44808385" conceptname="Pre-diabetes">Glucose Intolerance</span></a></h2>
<h2><a href="#section-6.5" class="toc">5.5 <span class="product-label-link" type="condition" conceptid="432585" conceptname="Blood coagulation disorder">Coagulopathy</span></a></h2>
<h1><a href="#section-7" class="toc">6  ADVERSE REACTIONS</a></h1>
<h2><a href="#section-7.1" class="toc">6.1 Clinical Trials Experience</a></h2>
<h2><a href="#section-7.2" class="toc">6.2 Clinical <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Allergic Reactions</span></a></h2>
<h2><a href="#section-7.3" class="toc">6.3 Immunogenicity</a></h2>
<h1><a href="#section-8" class="toc">7  DRUG INTERACTIONS</a></h1>
<h1><a href="#section-9" class="toc">8  USE IN SPECIFIC POPULATIONS</a></h1>
<h2><a href="#section-9.1" class="toc">8.1  Pregnancy</a></h2>
<h2><a href="#section-9.2" class="toc">8.3 Nursing Mothers</a></h2>
<h2><a href="#section-9.3" class="toc">8.4  Pediatric Use</a></h2>
<h2><a href="#section-9.4" class="toc">8.5  Geriatric Use</a></h2>
<h1><a href="#section-10" class="toc">10  OVERDOSAGE</a></h1>
<h1><a href="#section-11" class="toc">11  DESCRIPTION</a></h1>
<h1><a href="#section-12" class="toc">12  CLINICAL PHARMACOLOGY</a></h1>
<h2><a href="#section-12.1" class="toc">12.1  Mechanism of Action</a></h2>
<h2><a href="#section-12.2" class="toc">12.2  Pharmacodynamics</a></h2>
<h2><a href="#section-12.3" class="toc">12.3  Pharmacokinetics</a></h2>
<h1><a href="#section-13" class="toc">13  NONCLINICAL TOXICOLOGY</a></h1>
<h2><a href="#section-13.1" class="toc">13.1  Carcinogenesis, Mutagenesis, Impairment of Fertility</a></h2>
<h1><a href="#section-14" class="toc">14  CLINICAL STUDIES</a></h1>
<h2><a href="#section-14.1" class="toc">14.1 First-Line ALL</a></h2>
<h2><a href="#section-14.2" class="toc">14.2 ALL Patients Hypersensitive to Asparaginase</a></h2>
<h1><a href="#section-15" class="toc">16  HOW SUPPLIED/STORAGE AND HANDLING</a></h1>
<h1><a href="#section-16" class="toc">17  PATIENT COUNSELING INFORMATION</a></h1>
<h2><a href="#section-16.1" class="toc">17.1 Serious <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Allergic Reactions</span></a></h2>
<h2><a href="#section-16.2" class="toc">17.2 <span class="product-label-link" type="condition" conceptid="4130722" conceptname="Thrombosis">Thrombosis</span></a></h2>
<h2><a href="#section-16.3" class="toc">17.3 <span class="product-label-link" type="condition" conceptid="4192640" conceptname="Pancreatitis">Pancreatitis</span></a></h2>
<h2><a href="#section-16.4" class="toc">17.4 <span class="product-label-link" type="condition" conceptid="44808385" conceptname="Pre-diabetes">Glucose Intolerance</span></a></h2>
<dl class="Footnote">
<dt><a href="#footnote-reference-content" name="footnote-content">*</a></dt>
<dd>Sections or subsections omitted from the full prescribing information are not listed.</dd>
</dl>
</div></td></tr></table></div>
<div class="Contents">
<h1>FULL PRESCRIBING INFORMATION</h1>
<div class="Section">
<a name="section-1"></a><p></p>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="B2AD91AB-AA14-4E57-AAC8-EDB3F870F07C"></a><a name="section-2"></a><p></p>
<h1>1  INDICATIONS AND USAGE</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="E81603C2-F0E3-4180-841E-3D78B5CD8BE0"></a><a name="section-2.1"></a><p></p>
<h2>1.1 First Line <span class="product-label-link" type="condition" conceptid="134305" conceptname="Acute lymphoid leukemia">Acute Lymphoblastic Leukemia</span> (ALL)</h2>
<p class="First" style="border-left:1px solid;"><span class="XmChange">Oncaspar<span class="Sup">Â®</span> is indicated as a component of a multi-agent chemotherapeutic regimen for the first line treatment of patients with ALL.</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="DA8969B8-7548-45EC-9930-9207FBF2CA4B"></a><a name="section-2.2"></a><p></p>
<h2>1.2 <span class="product-label-link" type="condition" conceptid="134305" conceptname="Acute lymphoid leukemia">Acute Lymphoblastic Leukemia</span> and <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity</span> to Asparaginase</h2>
<p class="First">Oncaspar<span class="Sup">Â®</span> is indicated as a component of a multi-agent chemotherapeutic regimen for the treatment of patients with ALL and <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> to native forms of L-asparaginase.</p>
</div>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="B3CF70E8-DBA7-433F-A3AF-554144ACD1FD"></a><a name="section-3"></a><p></p>
<h1>2  DOSAGE AND ADMINISTRATION</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="AF77E56D-DD70-42C4-987D-AB20DCF8CE81"></a><a name="section-3.1"></a><p></p>
<h2>2.1 Recommended Dose</h2>
<p class="First">The recommended dose of Oncaspar<span class="Sup">Â®</span> is 2,500 IU/m<span class="Sup">2</span> intramuscularly (IM) or intravenously (IV). Oncaspar<span class="Sup">Â®</span> should be administered no more frequently than every 14 days.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="A3868AA5-D1ED-4CD6-9B0D-87D84C3CAFC7"></a><a name="section-3.2"></a><p></p>
<h2>2.2 Instructions for Administration</h2>
<p class="First">When Oncaspar<span class="Sup">Â®</span> is administered IM, the volume at a single injection site should be limited to 2 mL. If the volume to be administered is greater than 2 mL, multiple injection sites should be used.</p>
<p>When administered IV, Oncaspar<span class="Sup">Â®</span> should be given over a period of 1 to 2 hours in 100 mL of sodium chloride or dextrose injection 5%, through an infusion that is already running.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="A4A10BC7-5D33-4BB8-A9D1-0296CD5EA194"></a><a name="section-3.3"></a><p></p>
<h2>2.3 Preparation and Handling Precautions</h2>
<p class="First">Do not administer Oncaspar<span class="Sup">Â®</span> if drug has been:</p>
<ul>
<li>frozen</li>
<li>stored at room temperature (+15Â°C to +25Â°C; 59Â°F to 77Â°F) for more than 48 hours</li>
<li>shaken or vigorously <span class="product-label-link" type="condition" conceptid="436087" conceptname="Excitement">agitated</span> <span class="Italics">[see <a href="#AF3E374E-EB35-4DB8-BD3A-2EDD11CFC2BF">How Supplied/Storage and Handling (16)</a>]</span>
</li>
</ul>
<p>Parenteral drug products should be inspected visually for particulate matter, cloudiness, or discoloration prior to administration, whenever solution and container permit. If any of these are present, discard the vial.</p>
</div>
</div>
<div class="Section" data-sectionCode="43678-2">
<a name="FF701AF5-87FF-46FA-838D-CC2B5548A698"></a><a name="section-4"></a><p></p>
<h1>3  DOSAGE FORMS AND STRENGTHS</h1>
<p class="First">3,750 IU/5 mL single-use vial</p>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="B96ED3ED-EE6D-43E3-A106-C0FA789F66B8"></a><a name="section-5"></a><p></p>
<h1>4  CONTRAINDICATIONS</h1>
<ul>
<li>History of serious <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergic reactions</span> to Oncaspar<span class="Sup">Â®</span>
</li>
<li style="border-left:1px solid;"><span class="XmChange">History of serious <span class="product-label-link" type="condition" conceptid="4130722" conceptname="Thrombosis">thrombosis</span> with prior L-asparaginase therapy</span></li>
<li>History of <span class="product-label-link" type="condition" conceptid="4192640" conceptname="Pancreatitis">pancreatitis</span> with prior Lâ€‘asparaginase therapy</li>
<li>History of serious hemorrhagic events with prior L-asparaginase therapy</li>
</ul>
</div>
<div class="Section" data-sectionCode="43685-7">
<a name="ED7A3A65-C365-4CAB-968C-5BD8ECD5C5EF"></a><a name="section-6"></a><p></p>
<h1>5  WARNINGS AND PRECAUTIONS</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="F43A95EB-8471-40AC-BA00-AD3D0871E80F"></a><a name="section-6.1"></a><p></p>
<h2>5.1 <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">Anaphylaxis</span> and Serious <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Allergic Reactions</span></h2>
<p class="First">Serious <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergic reactions</span> can occur in patients receiving Oncaspar<span class="Sup">Â®</span>. The risk of serious <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergic reactions</span> is higher in patients with known <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> to other forms of L-asparaginase. Observe patients for 1 hour after administration of Oncaspar<span class="Sup">Â®</span> in a setting with resuscitation equipment and other agents necessary to treat <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylaxis</span> (for example, epinephrine, oxygen, intravenous steroids, antihistamines). Discontinue Oncaspar<span class="Sup">Â®</span> in patients with serious <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergic reactions</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="A8BEB43E-9C54-4106-8CFD-5FEDC8C3DE17"></a><a name="section-6.2"></a><p></p>
<h2>5.2 <span class="product-label-link" type="condition" conceptid="4130722" conceptname="Thrombosis">Thrombosis</span></h2>
<p class="First">Serious thrombotic events, including <span class="product-label-link" type="condition" conceptid="4290940" conceptname="Thrombosis of superior sagittal sinus">sagittal sinus thrombosis</span> can occur in patients receiving Oncaspar<span class="Sup">Â®</span>. Discontinue Oncaspar<span class="Sup">Â®</span> in patients with serious thrombotic events.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="C97ED96C-F64A-4678-BD35-52072A86324A"></a><a name="section-6.3"></a><p></p>
<h2>5.3 <span class="product-label-link" type="condition" conceptid="4192640" conceptname="Pancreatitis">Pancreatitis</span></h2>
<p class="First"><span class="product-label-link" type="condition" conceptid="4192640" conceptname="Pancreatitis">Pancreatitis</span> can occur in patients receiving Oncaspar<span class="Sup">Â®</span>. Evaluate patients with <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">abdominal pain</span> for evidence of <span class="product-label-link" type="condition" conceptid="4192640" conceptname="Pancreatitis">pancreatitis</span>. Discontinue Oncaspar<span class="Sup">Â®</span> in patients with <span class="product-label-link" type="condition" conceptid="4192640" conceptname="Pancreatitis">pancreatitis</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="A016C76D-E3AE-421E-AC91-12A10B009249"></a><a name="section-6.4"></a><p></p>
<h2>5.4 <span class="product-label-link" type="condition" conceptid="44808385" conceptname="Pre-diabetes">Glucose Intolerance</span></h2>
<p class="First"><span class="product-label-link" type="condition" conceptid="44808385" conceptname="Pre-diabetes">Glucose intolerance</span> can occur in patients receiving Oncaspar<span class="Sup">Â®</span>. In some cases, <span class="product-label-link" type="condition" conceptid="44808385" conceptname="Pre-diabetes">glucose intolerance</span> is irreversible.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="A5A0BA9F-A525-44ED-954D-600B56006FD2"></a><a name="section-6.5"></a><p></p>
<h2>5.5 <span class="product-label-link" type="condition" conceptid="432585" conceptname="Blood coagulation disorder">Coagulopathy</span></h2>
<p class="First">Increased <span class="product-label-link" type="condition" conceptid="4173906" conceptname="Clotting factor II assay">prothrombin</span> time, increased partial thromboplastin time, and <span class="product-label-link" type="condition" conceptid="4125644" conceptname="Hypofibrinogenemia">hypofibrinogenemia</span> can occur in patients receiving Oncaspar<span class="Sup">Â®</span>. Monitor coagulation parameters at baseline and periodically during and after treatment. Initiate treatment with fresh-frozen plasma to replace coagulation factors in patients with severe or symptomatic <span class="product-label-link" type="condition" conceptid="432585" conceptname="Blood coagulation disorder">coagulopathy</span>.</p>
</div>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="A038322E-2929-4DED-8320-B5A888855461"></a><a name="section-7"></a><p></p>
<h1>6  ADVERSE REACTIONS</h1>
<p class="First">The following serious adverse reactions occur with Oncaspar<span class="Sup">Â®</span> treatment <span class="Italics">[see <a href="#ED7A3A65-C365-4CAB-968C-5BD8ECD5C5EF">Warnings and Precautions (5)</a>]:</span></p>
<ul>
<li><span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">Anaphylaxis</span> and serious <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergic reactions</span></li>
<li>Serious <span class="product-label-link" type="condition" conceptid="4130722" conceptname="Thrombosis">thrombosis</span></li>
<li><span class="product-label-link" type="condition" conceptid="4192640" conceptname="Pancreatitis">Pancreatitis</span></li>
<li><span class="product-label-link" type="condition" conceptid="44808385" conceptname="Pre-diabetes">Glucose intolerance</span></li>
<li><span class="product-label-link" type="condition" conceptid="432585" conceptname="Blood coagulation disorder">Coagulopathy</span></li>
</ul>
<p>The most common adverse reactions with Oncaspar<span class="Sup">Â®</span> are <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergic reactions</span> (including <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylaxis</span>), <span class="product-label-link" type="condition" conceptid="4214376" conceptname="Hyperglycemia">hyperglycemia</span>, <span class="product-label-link" type="condition" conceptid="4192640" conceptname="Pancreatitis">pancreatitis</span>, central nervous system (CNS) <span class="product-label-link" type="condition" conceptid="4130722" conceptname="Thrombosis">thrombosis</span>, <span class="product-label-link" type="condition" conceptid="432585" conceptname="Blood coagulation disorder">coagulopathy</span>, <span class="product-label-link" type="condition" conceptid="4032334" conceptname="Hyperbilirubinemia">hyperbilirubinemia</span>, and elevated transaminases.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="A6FE4206-AE65-4FF5-B24E-34E59117B768"></a><a name="section-7.1"></a><p></p>
<h2>6.1 Clinical Trials Experience</h2>
<p class="First">Because clinical trials are conducted under widely varying conditions, the adverse reaction rates observed cannot be directly compared to rates in other clinical trials and may not reflect the rates observed in clinical practice.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="F8478413-C557-48C8-BC3E-DF5AE3E5C76A"></a><a name="section-7.1.1"></a><p></p>
<p class="First"><span class="Italics Underline">First-Line ALL</span></p>
<p>The data presented below are derived from 2 studies in patients with standard-risk ALL who received Oncaspar<span class="Sup">Â®</span> as a component of first-line multi-agent chemotherapy. Study 1 was a randomized (1:1), active-controlled study that enrolled 118 patients, with a median age of 4.7 years (1.1-9.9 years), of whom 54% were males and 65% White, 14% Hispanic, 8% Black, 8% Asian, and 6% other. Of the 59 patients in Study 1 who were randomized to Oncaspar<span class="Sup">Â®</span>, 48 patients (81%) received all 3 planned doses of Oncaspar<span class="Sup">Â®</span>, 6 (10%) received 2 doses, 4 (7%) received 1 dose, and 1 patient (2%) did not receive the assigned treatment. Study 2 is an ongoing, multi-factorial design study in which all patients received Oncaspar<span class="Sup">Â®</span>as a component of various multi-agent chemotherapy regimens; interim safety data are available for 2,770 patients. Study participants had a median age of 4 years (1-10 years), and were 55% male, 68% White, 18% Hispanic, 4% Black, 3% Asian, and 7% other. Per protocol, the schedule of Oncaspar<span class="Sup">Â®</span>varied by treatment arm, with intermittent doses of Oncaspar<span class="Sup">Â®</span> for up to 10 months.</p>
<p>In Study 1, detailed safety information was collected for pre-specified adverse reactions identified as asparaginase-induced adverse reactions and for grade 3 and 4 non-hematologic adverse reactions according to the Childrenâ€™s Cancer Group (CCG) Toxicity and Complication Criteria. The per-patient incidence, by treatment arm, for these selected adverse reactions occurring at a severity of grade 3 or 4 are presented in Table 1 below:</p>
<a name="eb1fa816-ccbe-402f-ba6a-36223439c559"></a><table>
<caption><span>TABLE 1 STUDY 1: PER-PATIENT INCIDENCE OF SELECTED GRADE 3 AND 4 ADVERSE REACTIONS</span></caption>
<tfoot><tr class="First Last"><td colspan="3">
<p class="First"><span class="ParagraphCaption"><span class="Sup">1</span></span><span class="product-label-link" type="condition" conceptid="4094657" conceptname="Aspartate aminotransferase">Aspartate aminotransferase</span>, <span class="product-label-link" type="condition" conceptid="4211515" conceptname="Alanine aminotransferase">alanine aminotransferase</span>.</p>
<p><span class="ParagraphCaption"><span class="Sup">2</span></span>Prolonged <span class="product-label-link" type="condition" conceptid="4173906" conceptname="Clotting factor II assay">prothrombin</span> time or partial thromboplastin time; or <span class="product-label-link" type="condition" conceptid="4125644" conceptname="Hypofibrinogenemia">hypofibrinogenemia</span>.</p>
</td></tr></tfoot>
<tbody class="Headless">
<tr class="First">
<td></td>
<td align="center">
<span class="Bold">Oncaspar<span class="Sup">Â®</span></span><br><span class="Bold">(n=58)</span>
</td>
<td align="center">
<span class="Bold">Native</span><br><span class="Bold Italics">E. coli<br></span><span class="Bold">Lâ€‘Asparaginase</span><br><span class="Bold">(n=59)</span>
</td>
</tr>
<tr>
<td class="Toprule">Abnormal Liver Tests</td>
<td class="Toprule" align="center">3 (5%)</td>
<td class="Toprule" align="center">5 (8%)</td>
</tr>
<tr>
<td>Â Â Â Â Elevated Transaminases<span class="Sup">1</span>
</td>
<td align="center">2 (3%)</td>
<td align="center">4 (7%)</td>
</tr>
<tr>
<td>Â Â Â Â <span class="product-label-link" type="condition" conceptid="4032334" conceptname="Hyperbilirubinemia">Hyperbilirubinemia</span></td>
<td align="center">1 (2%)</td>
<td align="center">1 (2%)</td>
</tr>
<tr>
<td><span class="product-label-link" type="condition" conceptid="4214376" conceptname="Hyperglycemia">Hyperglycemia</span></td>
<td align="center">3 (5%)</td>
<td align="center">2 (3%)</td>
</tr>
<tr>
<td>Central Nervous System<br><span class="product-label-link" type="condition" conceptid="4130722" conceptname="Thrombosis">Thrombosis</span></td>
<td align="center">2 (3%)</td>
<td align="center">2 (3%)</td>
</tr>
<tr>
<td><span class="product-label-link" type="condition" conceptid="432585" conceptname="Blood coagulation disorder">Coagulopathy</span><span class="Sup">2</span>
</td>
<td align="center">1 (2%)</td>
<td align="center">3 (5%)</td>
</tr>
<tr>
<td><span class="product-label-link" type="condition" conceptid="4192640" conceptname="Pancreatitis">Pancreatitis</span></td>
<td align="center">1 (2%)</td>
<td align="center">1 (2%)</td>
</tr>
<tr class="Last">
<td>Clinical <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Allergic Reactions</span> to<br>Asparaginase</td>
<td align="center">1 (2%)</td>
<td align="center">0</td>
</tr>
</tbody>
</table>
<p>Safety data were collected in Study 2 only for National Cancer Institute Common Toxicity Criteria (NCI CTC) version 2.0, grade 3 and 4 non-hematologic toxicities. In this study, the per-patient incidence for the following adverse reactions occurring during treatment courses in which patients received Oncaspar<span class="Sup">Â®</span> were: elevated transaminases, 11%; <span class="product-label-link" type="condition" conceptid="432585" conceptname="Blood coagulation disorder">coagulopathy</span>, 7%; <span class="product-label-link" type="condition" conceptid="4214376" conceptname="Hyperglycemia">hyperglycemia</span>, 5%; CNS <span class="product-label-link" type="condition" conceptid="4130722" conceptname="Thrombosis">thrombosis</span>/<span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">hemorrhage</span>, 2%; <span class="product-label-link" type="condition" conceptid="4192640" conceptname="Pancreatitis">pancreatitis</span>, 2%; clinical <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergic reaction</span>, 1%; and <span class="product-label-link" type="condition" conceptid="4032334" conceptname="Hyperbilirubinemia">hyperbilirubinemia</span>, 1%. There were 3 <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">deaths</span> due to <span class="product-label-link" type="condition" conceptid="4192640" conceptname="Pancreatitis">pancreatitis</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="DF2F8F6B-0C9D-4BEB-B222-B00F36F38935"></a><a name="section-7.1.2"></a><p></p>
<p class="First"><span class="Italics Underline">Previously Treated ALL</span></p>
<p>Adverse reaction information was obtained from 5 clinical trials that enrolled a total of 174 patients with relapsed ALL who received Oncaspar<span class="Sup">Â®</span> as a single agent or in combination with multi-agent chemotherapy. The toxicity profile of Oncaspar<span class="Sup">Â®</span> in patients with previously treated relapsed ALL is similar to that reported above with the exception of clinical <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergic reactions</span> (see <a href="#eb1fa816-aabf-402f-bc6c-36223439c669">Table 2</a>). The most common adverse reactions of Oncaspar<span class="Sup">Â®</span> were clinical <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergic reactions</span>, elevated transaminases, <span class="product-label-link" type="condition" conceptid="4032334" conceptname="Hyperbilirubinemia">hyperbilirubinemia</span>, and coagulopathies. The most common serious adverse events due to Oncaspar<span class="Sup">Â®</span> treatment were <span class="product-label-link" type="condition" conceptid="4130722" conceptname="Thrombosis">thrombosis</span> (4%), <span class="product-label-link" type="condition" conceptid="4214376" conceptname="Hyperglycemia">hyperglycemia</span> requiring insulin therapy (3%), and <span class="product-label-link" type="condition" conceptid="4192640" conceptname="Pancreatitis">pancreatitis</span> (1%).</p>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="AF589C5B-3643-40E1-8B48-2850C7F23D24"></a><a name="section-7.2"></a><p></p>
<h2>6.2 Clinical <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Allergic Reactions</span></h2>
<p class="First">Clinical <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergic reactions</span> include the following: <span class="product-label-link" type="condition" conceptid="256717" conceptname="Bronchospasm">bronchospasm</span>, <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span>, <span class="product-label-link" type="condition" conceptid="22350" conceptname="Edema of larynx">laryngeal edema</span>, local <span class="product-label-link" type="condition" conceptid="137193" conceptname="Erythema">erythema</span> or <span class="product-label-link" type="condition" conceptid="4275722" conceptname="Swelling">swelling</span>, systemic <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span>, and <span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">urticaria</span>.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="A896D130-C57A-42A9-845A-B3663874536B"></a><a name="section-7.2.1"></a><p></p>
<p class="First"><span class="Italics Underline">First-Line ALL</span></p>
<p>Among 58 Oncaspar<span class="Sup">Â®</span>-treated patients enrolled in Study 1, clinical <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergic reactions</span> were reported in 2 patients (3%). One patient experienced a grade 1 <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergic reaction</span> and the other grade 3 <span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">hives</span>; both occurred during the first delayed intensification phase of the study (see <a href="#eb1fa816-aabf-402f-bc6c-36223439c669">Table 2</a>).</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="A48B263B-7592-49D2-A823-0F89BB0D8C50"></a><a name="section-7.2.2"></a><p></p>
<p class="First"><span class="Italics Underline">Previously Treated ALL</span></p>
<p>Among 62 patients with relapsed ALL and prior <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity reactions</span> to asparaginase, 35 patients (56%) had a history of clinical <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergic reactions</span> to native <span class="Italics">Escherichia (E.) coli</span> L-asparaginase, and 27 patients (44%) had history of clinical <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergic reactions</span> to both native <span class="Italics">E. coli</span> and native <span class="Italics">Erwinia </span>Lâ€‘asparaginase. Twenty (32%) of these 62 patients experienced clinical <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergic reactions</span> to Oncaspar<span class="Sup">Â®</span> (see <a href="#eb1fa816-aabf-402f-bc6c-36223439c669">Table 2</a>).</p>
<p>Among 112 patients with relapsed ALL with no prior <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity reactions</span> to asparaginase, 11 patients (10%) experienced clinical <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergic reactions</span> to Oncaspar<span class="Sup">Â®</span> (see <a href="#eb1fa816-aabf-402f-bc6c-36223439c669">Table 2</a>).</p>
<a name="eb1fa816-aabf-402f-bc6c-36223439c669"></a><table width="350">
<caption><span>TABLE 2 INCIDENCE OF CLINICAL <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">ALLERGIC REACTIONS</span>, OVERALL AND BY SEVERITY GRADE</span></caption>
<tbody class="Headless">
<tr class="First">
<td></td>
<td align="center" colspan="4"><span class="Bold">Toxicity Grade, n (%)</span></td>
<td></td>
</tr>
<tr>
<td class="Botrule"><span class="Bold">Patient Status</span></td>
<td class="Botrule Toprule" align="center"><span class="Bold">1</span></td>
<td class="Botrule Toprule" align="center"><span class="Bold">2</span></td>
<td class="Botrule Toprule" align="center"><span class="Bold">3</span></td>
<td class="Botrule Toprule" align="center"><span class="Bold">4</span></td>
<td class="Botrule" align="center"><span class="Bold">Total</span></td>
</tr>
<tr>
<td>Previously<br>Hypersensitive<br>Patients (n=62)</td>
<td align="center">7 (11)</td>
<td align="center">8 (13)</td>
<td align="center">4 (6)</td>
<td align="center">1 (2)</td>
<td align="center">20 (32)</td>
</tr>
<tr>
<td>Non-<br>Hypersensitive<br>Patients (n=112)</td>
<td align="center">5 (4)</td>
<td align="center">4 (4)</td>
<td align="center">1 (1)</td>
<td align="center">1 (1)</td>
<td align="center">11 (10)</td>
</tr>
<tr class="Last">
<td class="Toprule">First Line (n=58)</td>
<td class="Toprule" align="center">1 (2)</td>
<td class="Toprule" align="center">0</td>
<td class="Toprule" align="center">1 (2)</td>
<td class="Toprule" align="center">0</td>
<td class="Toprule" align="center">2 (3)</td>
</tr>
</tbody>
</table>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="FEA8F7C4-DA12-4068-A333-9F375DA8E12D"></a><a name="section-7.3"></a><p></p>
<h2>6.3 Immunogenicity</h2>
<p class="First">As with all therapeutic proteins, there is a potential for immunogenicity, defined as development of binding and/or neutralizing antibodies to the product.</p>
<p>In Study 1, Oncaspar<span class="Sup">Â®</span>-treated patients were assessed for evidence of binding antibodies using an enzyme-linked immunosorbent assay (ELISA) method. The incidence of protocol-specified â€œhigh-titerâ€? antibody formation was 2% in Induction (n=48), 10% in Delayed Intensification 1 (n=50), and 11% in Delayed Intensification 2 (n=44). There is insufficient information to determine whether the development of antibodies is associated with an increased risk of clinical <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergic reactions</span>, altered pharmacokinetics, or loss of antiâ€‘leukemic efficacy.</p>
<p>The detection of antibody formation is highly dependent on the sensitivity and specificity of the assay, and the observed incidence of antibody positivity in an assay may be influenced by several factors including sample handling, concomitant medications, and underlying disease. Therefore, comparison of the incidence of antibodies to Oncaspar<span class="Sup">Â®</span> with the incidence of antibodies to other products may be misleading.</p>
</div>
</div>
<div class="Section" data-sectionCode="34073-7">
<a name="FCA79C5C-5851-43C1-9E5B-089560400D70"></a><a name="section-8"></a><p></p>
<h1>7  DRUG INTERACTIONS</h1>
<p class="First">No formal drug interaction studies, between Oncaspar<span class="Sup">Â®</span> and other drugs, have been performed.</p>
</div>
<div class="Section" data-sectionCode="43684-0">
<a name="B443BC54-A09A-458C-81C3-571D57C5B03D"></a><a name="section-9"></a><p></p>
<h1>8  USE IN SPECIFIC POPULATIONS</h1>
<div class="Section" data-sectionCode="42228-7">
<a name="B09CC60E-5728-49E9-B90D-695D2D914237"></a><a name="section-9.1"></a><p></p>
<h2>8.1  Pregnancy</h2>
<p class="First"><span class="Italics">Pregnancy Category C</span>. Animal reproduction studies have not been conducted with Oncaspar<span class="Sup">Â®</span>. It is also not known whether Oncaspar<span class="Sup">Â®</span> can cause fetal harm when administered to a pregnant woman or can affect reproduction capacity. Oncaspar<span class="Sup">Â®</span> should be given to a pregnant woman only if clearly needed.</p>
</div>
<div class="Section" data-sectionCode="34080-2">
<a name="F4911014-0D99-4B29-A274-3621D5363C2D"></a><a name="section-9.2"></a><p></p>
<h2>8.3 Nursing Mothers</h2>
<p class="First">It is not known whether Oncaspar<span class="Sup">Â®</span> is excreted in human milk. Because many drugs are excreted in human milk and because of the potential for serious adverse reactions in nursing infants from Oncaspar<span class="Sup">Â®</span>, a decision should be made to discontinue nursing or discontinue the drug, taking into account the importance of the drug to the mother.</p>
</div>
<div class="Section" data-sectionCode="34081-0">
<a name="AECD8495-9F09-4727-BF14-DE9645831B39"></a><a name="section-9.3"></a><p></p>
<h2>8.4  Pediatric Use</h2>
<p class="First"><span class="Italics">[see <a href="#B5FFD7DF-8CAD-4DE8-BF71-C8EA1B433BE4">Clinical Studies (14.1)</a>]</span></p>
</div>
<div class="Section" data-sectionCode="34082-8">
<a name="CCEB208A-CC87-423F-BA42-53017546DEB9"></a><a name="section-9.4"></a><p></p>
<h2>8.5  Geriatric Use</h2>
<p class="First">Clinical studies of Oncaspar<span class="Sup">Â®</span> did not include sufficient numbers of subjects aged 65 years and older to determine whether they respond differently than younger subjects.</p>
</div>
</div>
<div class="Section" data-sectionCode="34088-5">
<a name="BAA41A64-BF03-4B4C-8BE3-663307F660EC"></a><a name="section-10"></a><p></p>
<h1>10  OVERDOSAGE</h1>
<p class="First">Three patients received 10,000 IU/m<span class="Sup">2 </span>of Oncaspar<span class="Sup">Â®</span> as an intravenous infusion. One patient experienced a slight increase in liver enzymes. A second patient developed a <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span> 10 minutes after the start of the infusion, which was controlled with the administration of an antihistamine and by slowing down the infusion rate. A third patient did not experience any adverse reactions.</p>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="AE40ED23-47A5-4F1A-B1FF-B77C8AA9DB47"></a><a name="section-11"></a><p></p>
<h1>11  DESCRIPTION</h1>
<p class="First">Oncaspar<span class="Sup">Â®</span> (pegaspargase) is a modified version of the enzyme L-asparaginase. To produce Oncaspar<span class="Sup">Â®</span>, L-asparaginase is modified by covalently conjugating units of monomethoxypolyethylene glycol (PEG), molecular weight of 5,000, to the enzyme, forming the active ingredient PEG-L-asparaginase. The Lâ€‘asparaginase (L-asparagine amidohydrolase, type EC-2, EC 3.5.1.1) used in the manufacture of Oncaspar<span class="Sup">Â®</span> is derived from <span class="Italics">E. coli</span> and supplied by Ovation Pharmaceuticals (U.S. License No. 1688) under a shared manufacturing arrangement. Oncaspar<span class="Sup">Â®</span> activity is expressed in International Units (IU) according to the recommendation of the International Union of Biochemistry. One IU of L-asparaginase is defined as that amount of enzyme required to generate 1 Âµmol of <span class="product-label-link" type="condition" conceptid="4184927" conceptname="Ammonia">ammonia</span> per minute at pH 7.3 and 37Â°C.</p>
<p>Oncaspar<span class="Sup">Â®</span> is supplied as a clear, colorless, preservative-free, isotonic sterile solution in phosphate-buffered saline, pH 7.3. Each milliliter contains Oncaspar<span class="Sup">Â®</span> 750 IU Â± 20% (based on specific activity of at least 85 IU per milligram protein), 1.20 mg monobasic sodium phosphate, USP, 5.58 mg dibasic sodium phosphate, USP, and 8.50 mg sodium chloride, USP, in water for injection, USP.</p>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="EFC43D9F-540A-4C1A-99BC-B7594FEAF13E"></a><a name="section-12"></a><p></p>
<h1>12  CLINICAL PHARMACOLOGY</h1>
<div class="Section" data-sectionCode="43679-0">
<a name="BA36382C-306B-4AE1-8AD7-EDC96CBE8421"></a><a name="section-12.1"></a><p></p>
<h2>12.1  Mechanism of Action</h2>
<p class="First">The mechanism of action of Oncaspar<span class="Sup">Â®</span> is thought to be based on selective killing of leukemic cells due to depletion of plasma asparagine. Some leukemic cells are unable to synthesize asparagine due to a lack of asparagine synthetase and are dependent on an exogenous source of asparagine for survival. Depletion of asparagine, which results from treatment with the enzyme L-asparaginase, kills the leukemic cells. Normal cells, however, are less affected by the depletion due to their ability to synthesize asparagine.</p>
</div>
<div class="Section" data-sectionCode="43681-6">
<a name="C9574749-963F-454F-9B1E-2928B67842B0"></a><a name="section-12.2"></a><p></p>
<h2>12.2  Pharmacodynamics</h2>
<p class="First">In Study 1, pharmacodynamics were assessed in 57 newly diagnosed pediatric patients with standard-risk ALL who received three IM doses of Oncaspar<span class="Sup">Â®</span> (2,500 IU/m<span class="Sup">2</span>), one each during induction and two delayed intensification treatment phases. Pharmacodynamic activity was assessed through serial measurements of asparagine in sera (n=57) and cerebrospinal fluid (CSF) (n=50). The data for asparagine depletion are presented in CLINICAL STUDIES <span class="Italics">[see<a href="#CA6F18AA-40E5-487D-9974-8A7D121DCBC5">Clinical Studies (14)</a>]</span>.</p>
</div>
<div class="Section" data-sectionCode="43682-4">
<a name="FFC1E77A-E098-4A49-8766-D5DAA10AC169"></a><a name="section-12.3"></a><p></p>
<h2>12.3  Pharmacokinetics</h2>
<p class="First">Pharmacokinetic assessments were based on an enzymatic assay measuring asparaginase activity. Serum pharmacokinetics were assessed in 34 newly diagnosed pediatric patients with standard-risk ALL in Study 1 following IM administration of 2,500 IU/m<span class="Sup">2</span>. The elimination half-life of Oncaspar<span class="Sup">Â®</span> was approximately 5.8 days during the induction phase. Similar elimination half-lives were observed during Delayed Intensification 1 and Delayed Intensification 2. Concentrations greater than 0.1 IU/mL were observed in over 90% of the samples from patients treated with Oncaspar<span class="Sup">Â®</span> during induction, Delayed Intensification 1, and Delayed Intensification 2 for approximately 20 days.</p>
<p>In 3 pharmacokinetic studies, 37 patients with relapsed ALL received Oncaspar<span class="Sup">Â®</span>at 2,500 IU/m<span class="Sup">2</span> IM every 2 weeks. The plasma half-life of Oncaspar<span class="Sup">Â®</span> was 3.2 Â± 1.8 days in 9 patients who were previously hypersensitive to native <span class="Italics">E. coli</span> L-asparaginase and 5.7 Â± 3.2 days in 28 non-hypersensitive patients. The area under the plasma concentration-time curve (AUC) was 9.5 Â± 4.0 IU/mL/day in the previously hypersensitive patients and 9.8 Â± 6.0 IU/mL/day in the non-hypersensitive patients.</p>
</div>
</div>
<div class="Section" data-sectionCode="43680-8">
<a name="F69E1728-773D-4600-9354-AE240917F721"></a><a name="section-13"></a><p></p>
<h1>13  NONCLINICAL TOXICOLOGY</h1>
<div class="Section" data-sectionCode="34083-6">
<a name="D14268AE-1FAC-4C93-9297-791EB9202D39"></a><a name="section-13.1"></a><p></p>
<h2>13.1  Carcinogenesis, Mutagenesis, Impairment of Fertility</h2>
<ul>
<li>No long-term carcinogenicity studies in animals have been performed with Oncaspar<span class="Sup">Â®</span>.</li>
<li>No relevant studies addressing mutagenic potential have been conducted. Oncaspar<span class="Sup">Â®</span> did not exhibit a mutagenic effect when tested against <span class="Italics"><span class="product-label-link" type="condition" conceptid="4235289" conceptname="Salmonellosis">Salmonella</span> typhimurium</span> <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span> in the Ames assay.</li>
<li>No studies have been performed on impairment of fertility.</li>
</ul>
</div>
</div>
<div class="Section" data-sectionCode="34092-7">
<a name="CA6F18AA-40E5-487D-9974-8A7D121DCBC5"></a><a name="section-14"></a><p></p>
<h1>14  CLINICAL STUDIES</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="B5FFD7DF-8CAD-4DE8-BF71-C8EA1B433BE4"></a><a name="section-14.1"></a><p></p>
<h2>14.1 First-Line ALL</h2>
<p class="First">The safety and effectiveness of Oncaspar<span class="Sup">Â®</span> was evaluated in an open-label, multicenter, randomized, active-controlled study (Study 1). In this study, 118 pediatric patients aged 1 to 9 years with previously untreated standard-risk ALL were randomized 1:1 to Oncaspar<span class="Sup">Â®</span> or native <span class="Italics">E. coli</span> L-asparaginase as part of combination therapy. Oncaspar<span class="Sup">Â®</span> was administered IM at a dose of 2,500 IU/m<span class="Sup">2</span> on Day 3 of the 4â€‘week induction phase and on Day 3 of each of two 8-week delayed intensification phases. Native <span class="Italics">E. coli</span> Lâ€‘asparaginase was administered IM at a dose of 6,000 IU/m<span class="Sup">2</span> three times weekly for 9 doses during induction and for 6 doses during each delayed intensification phase.</p>
<p>The primary determination of effectiveness was based on demonstration of similar asparagine depletion (magnitude and duration) in the Oncaspar<span class="Sup">Â®</span> and native <span class="Italics">E. coli</span> L-asparaginase arms. The protocol-specified goal was achievement of asparagine depletion to a serum concentration of â‰¤1 Î¼M. The proportion of patients with this level of depletion was similar between the 2 study arms during all 3 phases of treatment at the protocol-specified time points.</p>
<p>In all phases of treatment, serum asparagine concentrations decreased within 4 days of the first dose of asparaginase in the treatment phase and remained low for approximately 3 weeks for both Oncaspar<span class="Sup">Â®</span> and native <span class="Italics">E. coli </span>L-asparaginase arms. Serum asparagine concentrations during the induction phase are shown in Figure 1. The patterns of serum asparagine depletion in the 2 delayed intensification phases are similar to the pattern of serum asparagine depletion in the induction phase.</p>
<p><img alt="Image from Drug Label Content" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=D046EC54-9AC8-4C9F-87A7-69E9900D8016&amp;name=oncaspar-figure-1.jpg"></p>
<p>Note: Â Â Oncaspar<span class="Sup">Â®</span> (2,500 IU/m<span class="Sup">2</span> IM) was administered on Day 3 <br>Â Â Â Â Â Â Â Â Â Â Â Â of the 4-week induction phase. Native <br>Â Â Â Â Â Â Â Â Â Â Â Â <span class="Italics">E. coli</span> Lâ€‘asparaginase (6,000 IU/m<span class="Sup">2</span> IM) was<br>Â Â Â Â Â Â Â Â Â Â Â Â administered 3 times weekly for 9 doses during induction.</p>
<p>CSF asparagine concentrations were determined in 50 patients during the induction phase. CSF asparagine decreased from a mean pretreatment concentration of 3.1 ÂµM to 1.7 ÂµM on Day 4 Â± 1 and 1.5 ÂµM 25 Â± 1 days after administration of Oncaspar<span class="Sup">Â®</span>. These findings were similar to those observed in the native <span class="Italics">E. coli </span>L-asparaginase treatment arm.</p>
<p>While the 3-year Event-Free Survival (EFS) for the Oncaspar<span class="Sup">Â®</span>and native <span class="Italics">E. coli</span> Lâ€‘asparaginase study arms were similar and in the range of 80%, Study 1 was not designed to evaluate for differences in EFS rates.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="FCBF362F-1249-4C39-B26A-0CE15D2E3FF8"></a><a name="section-14.2"></a><p></p>
<h2>14.2 ALL Patients Hypersensitive to Asparaginase</h2>
<p class="First">The safety and effectiveness of Oncaspar<span class="Sup">Â®</span> was evaluated in 4 open-label studies enrolling a total of 42 patients with multiply-relapsed, <span class="product-label-link" type="condition" conceptid="138708" conceptname="Acute leukemia">acute leukemia</span> [39 (93%) with ALL] with a history of prior clinical <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergic reaction</span> to asparaginase. <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity</span> to asparaginase was defined by a history of systemic <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span>, <span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">urticaria</span>, <span class="product-label-link" type="condition" conceptid="256717" conceptname="Bronchospasm">bronchospasm</span>, <span class="product-label-link" type="condition" conceptid="22350" conceptname="Edema of larynx">laryngeal edema</span>, <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span>, or local <span class="product-label-link" type="condition" conceptid="137193" conceptname="Erythema">erythema</span>, <span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">urticaria</span>, or <span class="product-label-link" type="condition" conceptid="4275722" conceptname="Swelling">swelling</span>, greater than 2 centimeters, for at least 10 minutes following administration of any form of native <span class="Italics">E. coli</span> L-asparaginase. All patients received Oncaspar<span class="Sup">Â®</span> at a dose of 2,000 or 2,500 IU/m<span class="Sup">2</span> administered IM or IV every 14 days. Patients received Oncaspar<span class="Sup">Â®</span> as a single agent or in combination with multi-agent chemotherapy. The reâ€‘induction response rate was 50% (95% confidence interval: 35%, 65%), based upon 36% complete remissions and 14% partial remissions. These results were similar to the overall response rates reported for patients with ALL receiving second-line, native <span class="Italics">E. coli</span> L-asparaginase-containing re-induction chemotherapy. Anti-tumor activity was also observed with single-agent Oncaspar<span class="Sup">Â®</span>. Three responses (1 complete remission and 2 partial remissions) were observed in 9 adult and pediatric patients with relapsed ALL and <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> to native <span class="Italics">E. coli</span> Lâ€‘asparaginase.</p>
</div>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="AF3E374E-EB35-4DB8-BD3A-2EDD11CFC2BF"></a><a name="section-15"></a><p></p>
<h1>16  HOW SUPPLIED/STORAGE AND HANDLING</h1>
<p class="First"><span class="Italics Underline">Dosage Form</span></p>
<p>NDC 57665-002-02</p>
<p>3,750 IU/5 mL single-use vial individually packaged in a carton</p>
<div class="Section" data-sectionCode="44425-7">
<a name="D70E4DB6-E608-4604-8267-145609202F89"></a><a name="section-15.1"></a><p></p>
<p class="First"><span class="Italics Underline">Storage and Handling</span></p>
<p>Keep refrigerated at +2Â°C to +8ÂºC (36Â°F to 46Â°F).</p>
<p>Use only one dose per vial; do not re-enter the vial. Discard unused portions. Do not save unused drug for later administration.</p>
<p>Do not administer Oncaspar<span class="Sup">Â®</span> if the drug:</p>
<ul>
<li>has been frozen</li>
<li>has been stored at room temperature (+15Â°C to +25Â°C; 59Â°F to 77Â°F) for more than 48 hours</li>
<li>has been shaken or vigorously <span class="product-label-link" type="condition" conceptid="436087" conceptname="Excitement">agitated</span></li>
<li>is cloudy, discolored, and precipitate is present.</li>
</ul>
</div>
</div>
<div class="Section" data-sectionCode="34076-0">
<a name="B9D6DA03-6355-4DC4-BB21-D7FF8969B234"></a><a name="section-16"></a><p></p>
<h1>17  PATIENT COUNSELING INFORMATION</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="B6A6079E-7271-4895-BD4F-FC01ECF7013E"></a><a name="section-16.1"></a><p></p>
<h2>17.1 Serious <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Allergic Reactions</span></h2>
<p class="First">Patients should be informed of the possibility of serious <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergic reactions</span>, including <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylaxis</span>, and to immediately report any <span class="product-label-link" type="condition" conceptid="4275722" conceptname="Swelling">swellings</span> or <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">difficulty breathing</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="E09AC254-92FD-4C87-9A51-7088129325D8"></a><a name="section-16.2"></a><p></p>
<h2>17.2 <span class="product-label-link" type="condition" conceptid="4130722" conceptname="Thrombosis">Thrombosis</span></h2>
<p class="First">Patients should be advised to immediately report any severe <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>. Arm or leg <span class="product-label-link" type="condition" conceptid="4275722" conceptname="Swelling">swelling</span>, acute <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">shortness of breath</span>, and <span class="product-label-link" type="condition" conceptid="77670" conceptname="Chest pain">chest pain</span> also should be reported immediately.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="DF95700D-A116-4AE9-9734-BA0B61DFA936"></a><a name="section-16.3"></a><p></p>
<h2>17.3 <span class="product-label-link" type="condition" conceptid="4192640" conceptname="Pancreatitis">Pancreatitis</span></h2>
<p class="First">Patients should be advised to immediately report any severe <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">abdominal pain</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="E53608CA-8A65-4C93-A92D-73C0C1AD5915"></a><a name="section-16.4"></a><p></p>
<h2>17.4 <span class="product-label-link" type="condition" conceptid="44808385" conceptname="Pre-diabetes">Glucose Intolerance</span></h2>
<p class="First">Patients should be advised to report <span class="product-label-link" type="condition" conceptid="4241197" conceptname="Thirst">excessive thirst</span> or any increase in the volume or frequency of urination.</p>
<p>U.S. License No. 1171</p>
</div>
</div>
</div>
<div class="DataElementsTables"><table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>ONCASPARÂ 		
					</strong><br><span class="contentTableReg">pegaspargase injection, solution</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem"></td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:57665-002</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">INTRAMUSCULAR, INTRAVENOUS</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">Â Â Â Â 
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>pegaspargase</strong> (pegaspargase) </td>
<td class="formItem"></td>
<td class="formItem">750Â [iU] Â inÂ 1Â mL</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>sodium phosphate, monobasic</strong></td>
<td class="formItem">1.2Â mg Â inÂ 1Â mL</td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>sodium phosphate, dibasic</strong></td>
<td class="formItem">5.58Â mg Â inÂ 1Â mL</td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>sodium chloride</strong></td>
<td class="formItem">8.5Â mg Â inÂ 1Â mL</td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>water</strong></td>
<td class="formItem">Â </td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:57665-002-02</td>
<td class="formItem">1  in 1 CARTON</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem"></td>
<td class="formItem">5 mL in 1 VIAL, SINGLE-USE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"></td></tr>
</tbody></table></div>
<p><div class="EffectiveDate">Revised: 7/2006<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>A48CF56F-A853-AF02-2FE0-5643C9442160</div>
<div>Set id: D046EC54-9AC8-4C9F-87A7-69E9900D8016</div>
<div>Version: 1</div>
<div>Effective Time: 20060724</div>
</div>
</div>Â <div class="DistributorName"></div></p>
</body></html>
